X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (32) 32
humans (30) 30
male (25) 25
female (23) 23
middle aged (22) 22
aged (21) 21
hematology (21) 21
aged, 80 and over (17) 17
adult (16) 16
azacitidine - therapeutic use (14) 14
antimetabolites, antineoplastic - therapeutic use (13) 13
cancer (12) 12
leukemia, myeloid, acute - drug therapy (12) 12
myelodysplastic syndromes - drug therapy (12) 12
oncology (11) 11
treatment outcome (11) 11
retrospective studies (10) 10
azacitidine (9) 9
myelodysplastic syndromes - mortality (9) 9
acute myeloid-leukemia (7) 7
conventional care regimens (7) 7
leukemia, myeloid, acute - mortality (7) 7
prognosis (7) 7
survival (7) 7
leukemia, myeloid, acute - pathology (6) 6
life sciences (6) 6
risk factors (6) 6
survival rate (6) 6
abridged index medicus (5) 5
acute myelogenous leukemia (5) 5
acute myeloid leukemia (5) 5
analysis (5) 5
antimetabolites, antineoplastic - administration & dosage (5) 5
azacitidine - administration & dosage (5) 5
azacitidine - analogs & derivatives (5) 5
chemotherapy (5) 5
cytogenetics (5) 5
decitabine (5) 5
follow-up studies (5) 5
hematology, oncology and palliative medicine (5) 5
international working group (5) 5
treatment failure (5) 5
care and treatment (4) 4
cell lung-cancer (4) 4
cohort studies (4) 4
disease-free survival (4) 4
kaplan-meier estimate (4) 4
mds (4) 4
mortality (4) 4
myelodysplastic syndrome (4) 4
myelodysplastic syndromes (4) 4
myelodysplastic syndromes - diagnosis (4) 4
neoplasms (4) 4
recurrence (4) 4
remission induction (4) 4
survival analysis (4) 4
[ sdv.can ] life sciences [q-bio]/cancer (3) 3
acute promyelocytic leukemia (3) 3
allogeneic stem cell transplantation (3) 3
antineoplastic agents - therapeutic use (3) 3
apoptosis (3) 3
binding (3) 3
biology (3) 3
bioscience (3) 3
calcium (3) 3
cell (3) 3
cell biology (3) 3
cell transplantation (3) 3
cycle (3) 3
cytarabine - therapeutic use (3) 3
cytogenetic analysis (3) 3
disease progression (3) 3
diseases (3) 3
efficacy (3) 3
erlotinib hydrochloride (3) 3
france (3) 3
in-vitro (3) 3
intensive chemotherapy (3) 3
landes (3) 3
leukemia (3) 3
leukemia, myeloid, acute - etiology (3) 3
leukemia, myeloid, acute - metabolism (3) 3
medical prognosis (3) 3
mitochondrial alterations (3) 3
multicenter (3) 3
myelodysplastic syndromes - etiology (3) 3
myelodysplastic syndromes - genetics (3) 3
older patients (3) 3
organogenesis (3) 3
pharmacology & pharmacy (3) 3
prognostic-factors (3) 3
proteins (3) 3
relapse (3) 3
response criteria (3) 3
stem cells (3) 3
therapy (3) 3
transplantation (3) 3
5-aza-2'-deoxycytidine (2) 2
aml (2) 2
animals (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 08/2017, Volume 318, Issue 6, pp. 557 - 566
IMPORTANCE: Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant... 
MEDICINE, GENERAL & INTERNAL | LUNG TRANSPLANTATION | BRONCHIOLITIS OBLITERANS SYNDROME | THERAPY | EFFICACY | REJECTION | PULMONARY COMPLICATIONS | RISK | MICROBIOTA | LEUKEMIA | VERSUS-HOST-DISEASE | Hematologic Neoplasms - therapy | Recurrence | Double-Blind Method | Bronchiolitis Obliterans - etiology | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Transplantation, Homologous | Bronchiolitis Obliterans - prevention & control | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Disease-Free Survival | Azithromycin - therapeutic use | Treatment Failure | Hematopoietic Stem Cell Transplantation - adverse effects | Intention to Treat Analysis | Adult | Female | Anti-Bacterial Agents - adverse effects | Respiratory Function Tests | Transplantation Conditioning | Complications and side effects | Usage | Patient outcomes | Analysis | Lung diseases | Azithromycin | Stem cells | Dosage and administration | Transplantation | Pulmonary ventilation | Drug therapy | Risk factors | Respiratory function | Transplants & implants | Syngeneic grafts | Lung | Bronchopneumonia | Lung transplantation | Clinical trials | Stem cell transplantation | Malignancy | Incidence | Randomization | Motivation | Safety engineering | Bronchiolitis obliterans | Cell survival | Hematology | Mortality | Patients | Survival | Morbidity | Hemopoiesis | Air flow | Respiratory diseases | Pulmonary functions | Index Medicus | Abridged Index Medicus | Original Investigation | Research
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2014, Volume 89, Issue 4, pp. 410 - 416
Journal Article
Cell Cycle, ISSN 1538-4101, 11/2012, Volume 11, Issue 21, pp. 4079 - 4092
Erlotinib was originally developed as an epidermal growth factor receptor (EGFR)-specific inhibitor for the treatment of solid malignancies, yet also exerts... 
cytarabine | 3 | verapamil | VP16 | DiOC | calcein | MK-571 | KO-143 | Proteins | Binding | Landes | Calcium | Biology | Bioscience | Cell | Cycle | Organogenesis | Cancer | Verapamil | Cytarabine | Calcein | PROGNOSTIC IMPACT | ACUTE MYELOGENOUS LEUKEMIA | MULTIDRUG-RESISTANCE PROTEIN | DRUG-RESISTANCE | P-GLYCOPROTEIN | CELL BIOLOGY | CELL LUNG-CANCER | IN-VITRO | SOUTHWEST-ONCOLOGY-GROUP | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Erlotinib Hydrochloride | Neoplastic Stem Cells - cytology | Antigens, CD34 - metabolism | Apoptosis - drug effects | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myeloid, Acute - metabolism | Middle Aged | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Neoplasm Proteins - metabolism | Antineoplastic Agents - toxicity | Neoplastic Stem Cells - metabolism | ATP-Binding Cassette Transporters - metabolism | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Leukemia, Myeloid, Acute - pathology | Multidrug Resistance-Associated Proteins - antagonists & inhibitors | Down-Regulation - drug effects | Quinazolines - toxicity | Quinazolines - therapeutic use | Cell Line, Tumor | Aged | Multidrug Resistance-Associated Proteins - metabolism | ATP-Binding Cassette Transporters - antagonists & inhibitors | Index Medicus | Report | DiOC2
Journal Article
Cell Cycle, ISSN 1538-4101, 07/2011, Volume 10, Issue 14, pp. 2323 - 2330
Journal Article
Journal Article
International Journal of Nanomedicine, ISSN 1176-9114, 2019, Volume 14, pp. 2091 - 2102
Journal Article
Leukemia Research, ISSN 0145-2126, 2014, Volume 39, Issue 2, pp. 124 - 130
Journal Article
Journal Article
Transplantation, ISSN 0041-1337, 02/2017, Volume 101, Issue 2, pp. 437 - 444
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2009, Volume 27, Issue 28, pp. 4747 - 4753
Journal Article
Journal Article